SYNBIOTIC SE and IBU-tec Advanced Materials report corporate updates

SYNBIOTIC SE is undergoing a fundamental shift in its investment profile following a series of insolvencies and liquidations across its portfolio, including Bushdoctor, Hempro International, SOLIDMIND Group, and Lean Labs Pharma. The company has halted intra-group funding to protect liquidity due to declining CBD and hemp demand and regulatory uncertainty. The remaining core operations will focus on WEECO Pharma, a German medical cannabis importer and wholesaler, alongside MH medical hemp and the Croatian manufacturer Ilesol.

IBU-tec Advanced Materials AG has reported its 2026 half-year results, confirming its guidance and showing progress in its capacity expansion. The company's battery business, specifically LFP cathode materials, grew by 20.7% year-over-year to 5.9 million EUR. Total group revenue rose slightly by 3.9% to 19.7 million EUR. While the glass coating segment saw a significant decline, the special chemistry division showed signs of recovery, and EBITDA remained stable at 2.0 million EUR.